Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09:53a AstraZeneca shares plunge 15 percent as lung cancer study fails
08:18a ASTRAZENECA : Az & merck establish strategic oncology deal
08:13a MERCK AND : AstraZeneca and Merck Establish Strategic Oncology Collaboration
07/25 MERCK : Announces Fourth-Quarter 2017 Dividend
07/25MERCK & CO., INC. : half-yearly earnings release
07/25 MERCK : ’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpo..
07/25 PFIZER : Corning, with assists from Pfizer and Merck, plans $500M pharma glass p..
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24 MERCK : Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherap..
07/24DJSamsung Releases Arthritis Drug in First Foray Into U.S. Pharmaceuticals
More news
News from SeekingAlpha
07/26 20 Top Stocks For A Monthly Dividend Portfolio
07/26 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 26, 2017
07/25 Merck declares $0.47 dividend
07/25 ARALEZ : A Quick Overview Of The Investment Thesis
07/25 Samsung Leaps Into Its First U.S. Biosimilars Battle
Financials ($)
Sales 2017 40 070 M
EBIT 2017 13 715 M
Net income 2017 7 101 M
Debt 2017 5 065 M
Yield 2017 3,04%
P/E ratio 2017 22,99
P/E ratio 2018 17,90
EV / Sales 2017 4,34x
EV / Sales 2018 4,19x
Capitalization 169 033 M
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.98%169 033
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.69%220 651
ROCHE HOLDING LTD.4.08%220 599
PFIZER1.91%197 115
SANOFI7.06%121 268